filmov
tv
Dr. Michael J. Overman on Immunotherapy in Colorectal Cancer
Показать описание
OncLive
cancer
oncology
Рекомендации по теме
0:01:31
Dr. Michael J. Overman on Immunotherapy in Colorectal Cancer
0:01:37
Dr. Overman on Next Steps With Immunotherapy in mCRC
0:01:09
Dr. Overman on Second-Line Therapy Options for Colorectal Cancer
0:01:29
Dr. Overman on Tailoring Approaches to Molecular Subsets in mCRC
0:01:42
Dr. Overman on the Impact of Nivolumab in mCRC
0:01:03
Dr. Overman on Implications of Tumor Location Data for Patients With mCRC
0:01:18
Dr. Overman on Unmet Needs With Immunotherapy in mCRC
0:02:15
Dr. Overman Discusses ReDOS Study in mCRC
0:01:22
Dr. Overman on Potential Applications of ctDNA in Colorectal Cancer
0:02:00
Dr. Overman on Nivolumab and Ipilimumab in Patients With MSI-H CRC
0:02:32
Dr. Overman Discusses Updated Findings of CheckMate-142 in Patients With MSI-H mCRC
0:01:05
Nivolumab and Ipilimumab Combination in Frontline mCRC
0:01:46
Dr. Overman on Investigational Targeted Therapies in mCRC
0:01:15
Dr. Overman Discusses Progress With Immunotherapy in GI Cancer
0:01:27
Dr. Overman on Ongoing Research With Immunotherapy in MSS CRC
0:27:09
Interdisciplinary Approaches to Personalizing Immunotherapy in Metastatic CRC
0:01:24
Dr. Overman on Updated Findings With Nivolumab in Metastatic CRC
0:01:28
Dr. Overman on Distinctions Between Regorafenib and TAS-102 in CRC
0:02:33
Updated Results for Nivolumab in MSI-H Colorectal Cancer
0:01:38
Dr. Overman on Remaining Questions With Immunotherapy in CRC
0:01:30
Dr. Overman on the Combination of Atezolizumab and Bevacizumab in HCC
0:02:03
Promising CheckMate-142 Data for Second-Line Ipilimumab Plus Nivolumab in mCRC
0:01:05
Dr. Overman on Molecular Subtypes in CRC
0:00:54
MSI Testing Is Crucial in Colorectal Cancer
0:01:31
0:01:37
0:01:09
0:01:29
0:01:42
0:01:03
0:01:18
0:02:15
0:01:22
0:02:00
0:02:32
0:01:05
0:01:46
0:01:15
0:01:27
0:27:09
0:01:24
0:01:28
0:02:33
0:01:38
0:01:30
0:02:03
0:01:05
0:00:54